Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy

Tomas Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrasa, Nuria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Pare, Patricia GalvanLisa A. Carey, Charles M. Perou, Aleix Prat

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Purpose: We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer. The PAM50-based chemoendocrine score (CES) predicts chemo-endocrine sensitivity in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer. Here, we evaluate the relationship of CES with response and survival in HRþ/HER2þ breast cancer. Experimental Design: Intrinsic subtype and clinicopathologic data were obtained from seven studies in which patients were treated with HER2-targeted therapy either with endocrine therapy (ET) or with chemotherapy (CTX). CES was evaluated as a continuous variable and categorically from low to high scores [CES-C (chemo-sensitive), CES-U (uncertain), and CES-E (endocrine-sensitive)]. We first analyzed each dataset individually, and then all combined. Multivariable analyses were used to test CES association with pathologic complete response (pCR) and disease-free survival (DFS). Results: A total of 457 patients were included (112 with ET and 345 with CTX). In the combined cohort, CES-C, CES-U, and CES-E were identified in 60%, 23%, and 17% of the patients, respectively. High CES (i.e., CES-E) was associated with a lower probability of achieving pCR independently of clinical characteristics, therapy, intrinsic subtype, and study (adjusted OR ¼ 0.42; P ¼ 0.016). A total of 295 patients were analyzed for DFS with a median follow-up of 66 months. High CES was also associated with better DFS (adjusted HR, 0.174; P ¼ 0.003) independently of pCR, clinical characteristics and intrinsic subtype. In patients with residual disease, the adjusted DFS HR of CES was 0.160 (P ¼ 0.012). Conclusions: In HER2þ/HRþ breast cancer, CES is useful for predicting chemo-endocrine sensitivity and provides additional prognostication beyond intrinsic subtype and clinicopathologic characteristics.

Original languageEnglish
Pages (from-to)3116-3125
Number of pages10
JournalClinical Cancer Research
Volume27
Issue number11
DOIs
Publication statusPublished - Jun 1 2021
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy'. Together they form a unique fingerprint.

Cite this